This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 1 of 1 for:    P-CD19CD20-ALLO1
Previous Study | Return to List | Next Study

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06014762
Recruitment Status : Recruiting
First Posted : August 28, 2023
Last Update Posted : April 8, 2024
Information provided by (Responsible Party):
Poseida Therapeutics, Inc.

Brief Summary:
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Chronic Lymphocytic Leukemia Biological: P-CD19CD20-ALLO1 Drug: Rimiducid Phase 1

Detailed Description:
Phase 1 study consisting of two parts. Part 1 is a weight-based dose escalation following a 3+3 design of dose-escalating cohorts to define a maximum tolerated dose (MTD). Part 2 includes administration at a selected dose and LD regimen. After enrollment, subjects may receive a lymphodepletion therapy regimen before administration of allogeneic CAR-T cells, administered as a single dose. Treated subjects will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
Estimated Study Start Date : April 2024
Estimated Primary Completion Date : March 2029
Estimated Study Completion Date : March 2041

Arm Intervention/treatment
Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm S)

P-CD19CD20-ALLO1 following conditioning chemotherapy regimen S.

Rimiducid may be administered.

Biological: P-CD19CD20-ALLO1
Single weight-based IV administration

Drug: Rimiducid
Single weight-based IV administration

Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 750)

P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 750.

Rimiducid may be administered.

Biological: P-CD19CD20-ALLO1
Single weight-based IV administration

Drug: Rimiducid
Single weight-based IV administration

Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 1000)

P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 1000.

Rimiducid may be administered.

Biological: P-CD19CD20-ALLO1
Single weight-based IV administration

Drug: Rimiducid
Single weight-based IV administration

Primary Outcome Measures :
  1. To assess the safety and MTD of P-CD19CD20-ALLO1 based on dose limiting toxicities (DLT) [ Time Frame: Baseline through 28 days ]
    Number of subjects with DLT at each dose level to define an MTD

Secondary Outcome Measures :
  1. The safety of P-CD19CD20-ALLO1 (AEs) [ Time Frame: Baseline through 36 months ]
    Incidence and severity of adverse events (AEs)

  2. The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (ORR) [ Time Frame: Baseline through 15 years ]
    Overall Response Rate (ORR) - Percentage of patients with complete response (CR) or partial response (PR)

  3. The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (DOR) [ Time Frame: Baseline through 15 years ]
    Duration of Response - Time from complete response (CR) or partial response (PR) to progressive disease

  4. The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (PFS) [ Time Frame: Baseline through 15 years ]
    Progression Free Survival (PFS) - Time from P-CD19CD20-ALLO1 treatment to progressive disease

  5. The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (OS) [ Time Frame: Baseline through 15 years ]
    Overall Survival (OS) - Duration of survival from time of treatment with P-CD19CD20-ALLO1

  6. • The effect of cell dose and LD regimen to guide selection of specific cell dose and LD regimen for further assessment in Phase 2/3 studies [ Time Frame: Baseline through 36 months ]
    o Cytokine release syndrome (CRS) graded using American Society for Transplantation and Cellular Therapy (ASTCT) criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must have signed written, informed consent.
  2. Males or females ≥ 18 years of age.
  3. Must have prior biopsy proven confirmed diagnosis of DLBCL, FL, MCL, MZL, PMBCL, or CLL.
  4. Diagnosis of one of the following:

    1. DLBCL, FL, MCL, MZL, or PMBCL by World Health Organization (WHO) 2016 (Swerdlow, 2016) criteria
    2. CLL that meets published diagnostic criteria (Hallek, 2018):

    i. Monoclonal B cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B cell marker (CD19, CD20, or CD23) and CD5.

    ii. Prolymphocytes comprising ≤ 55% of blood lymphocytes. iii. Presence of ≥ 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood (at any point since initial diagnosis).

  5. CLL must be documented as CD20-positive.
  6. CLL must be documented as active disease meeting ≥ 1 of the following iwCLL 2018 criteria (Hallek, 2018) for requiring treatment:

    1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/μL)
    2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
    3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
    4. Progressive lymphocytosis with an increase of > 50% over a 2 month period or a lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte count (ALC) obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of < 30 × 109/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
    5. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:

    i. Unintentional weight loss ≥ 10% within the previous 6 months before Screening.

    ii. Significant fatigue (inability to work or perform usual activities). iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before Screening without evidence of infection.

    iv. Night sweats for > 1 month before Screening without evidence of infection.

  7. DLBCL, FL, MCL, MZL, or PMBCL must have measurable disease as defined by Lugano 2016 criteria (Cheson, 2016).
  8. Must have relapsed/refractory disease as defined by the following:

    1. DLBCL, FL, MCL, or PMBCL: received at least 2 prior lines of therapy that must include rituximab, cyclophosphamide, doxorubicin hydrochloride (i.e., hydroxydaunomycin), vincristine sulfate (i.e., oncovin), and prednisone (R-CHOP) or equivalent regimen and either autologous stem cell transplant (ASCT) or autologous CD19 targeting CAR-T therapy, or not a candidate for ASCT or autologous CD19 targeting CAR-T.


    2. MZL: received at least 2 prior lines of therapy that must include a CD20 monoclonal antibody (mAb) and a Bruton tyrosine kinase inhibitor (BTKi) OR
    3. CLL: received at least 2 prior lines of therapy that must include a CD20 mAb and a BTKi
  9. Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-CD19CD20-ALLO1 administration (both males and females of childbearing potential).
  10. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion chemotherapy regimen (females of childbearing potential).
  11. Must be at least 90 days since ASCT, if performed.
  12. Must be at least 3 months since autologous CAR-T therapy if such therapy was administered (medical monitor must approve prior CAR T therapy or other prior T cell targeted therapy).
  13. Must have adequate vital organ function, defined as follows (or medical monitor approval):

    1. Serum creatinine ≤ 1.5 mg/dL or estimated creatinine clearance

      ≥ 30 mL/min as calculated using the Cockcroft Gault formula and not dialysis-dependent.

    2. Adequate hematologic function, including:

    i. Absolute neutrophil count (ANC) ≥ 1000/μL in the absence of growth factor support (granulocyte-colony stimulating factor [G-CSF] within 7 days or peg-G-CSF within 14 days) ii. Platelet count ≥ 50,000/μL in the absence of transfusion support (platelet transfusion within 7 days) iii. Hemoglobin ≥ 8 g/dL in the absence of transfusion support (red blood cell count or whole blood within 7 days) c. Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 3 × the upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL (unless there is a history of Gilbert's Syndrome in which case bilirubin levels ≤ 3 mg/dL).

    d. Left ventricular ejection fraction (LVEF) ≥ 45%. LVEF assessment must have been performed within 4 weeks of enrollment.

  14. Must have recovered from toxicities due to prior therapies to Grade ≤ 2 according to the NCI CTCAE v5.0 criteria or to the subject's prior baseline.
  15. Must have an ECOG performance status of 0 to 1.

Exclusion Criteria:

  1. Is pregnant or lactating.
  2. Has inadequate venous access.
  3. Has active hemolytic anemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), disseminated intravascular coagulation, leukostasis, or amyloidosis.
  4. Has an active second malignancy (not disease-free for at least 5 years) in addition to non-Hodgkin lymphoma or CLL, excluding low-risk neoplasms such as non-metastatic basal cell or cutaneous squamous cell carcinoma.
  5. Has active autoimmune disease, such as psoriasis, multiple sclerosis, lupus, rheumatoid arthritis, etc. (the medical monitor will determine if a disease is active and autoimmune).
  6. Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, primary CNS lymphoma, etc. (the medical monitor will determine if significant).
  7. Has an active systemic infection (e.g., causing fevers or requiring antimicrobial treatment).
  8. Has a history of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome. Subjects with a history of treated hepatitis C can be enrolled if negative by hepatitis C polymerase chain reaction (PCR) on multiple occasions and with medical monitor approval.
  9. Is positive for human herpes virus (HHV)-6 or HHV-7 infection by polymerase chain reaction (PCR) at the Screening Visit (subjects may be included in the study if they are HHV-6 or HHV-7 IgG antibody-positive but PCR-negative).
  10. Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia (e.g., atrial fibrillation, sustained [> 30 seconds] ventricular tachyarrhythmias, etc.).
  11. Has any psychiatric or medical disorder (e.g., cardiovascular, endocrine, renal, gastrointestinal, genitourinary, immunodeficiency or pulmonary disorder not otherwise specified) that would, in the opinion of the Investigator or medical monitor, preclude safe participation in and/or adherence to the protocol (including medical conditions or laboratory findings that indicate a significant probability of not qualifying for or being unable to undergo, LD chemotherapy and/or CAR-T cell administration).
  12. Has received non-mAb anti-cancer medications within 2 weeks of the time of initiating LD chemotherapy.
  13. Has received mAb therapy within 4 weeks of initiating LD chemotherapy.
  14. Has received immunosuppressive medications within 2 weeks of the time of administration of P-CD19CD20-ALLO1, and/or expected to require them while on study (the medical monitor will determine if a medication is considered immunosuppressive).
  15. Has received systemic corticosteroid therapy ≥ 5 mg/day of prednisone or equivalent dose of another corticosteroid within 1 week or 5 half-lives (whichever is shorter) of the administration of P-CD19CD20-ALLO1 or is expected to require it during the course of the study. (Topical and inhaled steroids are permitted. Systemic corticosteroids are contraindicated after receiving P-CD19CD20-ALLO1 cells outside of study-specific guidance).
  16. Has CNS metastases or CNS involvement (including leptomeningeal carcinomatosis, cranial neuropathies or mass lesions, cauda equina syndrome and spinal cord compression).
  17. Has a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
  18. Has a history of having undergone allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days. Subjects with prior history of allogeneic stem cell transplant may be enrolled if they are not on immunosuppressive medications and with medical monitor approval.
  19. Has received prior allogeneic genetically modified cellular therapy or was treated with experimental allogeneic cell therapy.
  20. History or Grade ≥ 3 HLH/MAS or neurotoxicity with prior therapies (all symptoms of HLH/MAS, neurotoxicity, or CRS from prior therapies must be resolved at the time of enrollment).
  21. Has positive DAT at Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT06014762

Layout table for location contacts
Contact: Angie Schinkel 858-779-3103

Layout table for location information
United States, California
University of California San Diego Not yet recruiting
La Jolla, California, United States, 92093
Loma Linda University Cancer Center Not yet recruiting
Loma Linda, California, United States, 92354
United States, Michigan
Wayne State - Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
United States, New York
Weill Cornell Medicine Not yet recruiting
New York, New York, United States, 10021
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Not yet recruiting
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45206
United States, Oklahoma
University of Oklahoma, Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, South Carolina
Prisma Health - Upstate Cancer Institute Recruiting
Greenville, South Carolina, United States, 29605
United States, Tennessee
Vanderbilt University Medical Center Not yet recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor Scott & White Research Institute Recruiting
Dallas, Texas, United States, 75204
Sponsors and Collaborators
Poseida Therapeutics, Inc.
Layout table for investigator information
Study Director: Rajesh Belani, MD Vice President, Clinical Development
Layout table for additonal information
Responsible Party: Poseida Therapeutics, Inc. Identifier: NCT06014762    
Other Study ID Numbers: P-CD19CD20-ALLO1-001
First Posted: August 28, 2023    Key Record Dates
Last Update Posted: April 8, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Hematologic Diseases
Leukemia, B-Cell
Chronic Disease
Disease Attributes
Pathologic Processes